Articles from ClostraBio, Inc.

ClostraBio, Inc., a biotech company pioneering microbiome-based solutions for gastrointestinal health, today announced that its unique, next-generation probiotic strain, Anaerostipes caccae CLB101™, has been granted self-affirmed GRAS (Generally Recognized as Safe) status by a panel of scientific experts. This milestone clears the path for CLB101™ to enter the U.S. market as the first and only commercially available strain of Anaerostipes caccae.

ClostraBio, Inc., a biotechnology company focused on harnessing natural pathways to manage gut health, recently announced new institutional investors in their latest bridge financing round that includes capital from the Illinois Innovation Venture Fund (INVENT) and NextGen Nutrition Investment Partners (NGN). The INVENT program, administered by the Office of Entrepreneurship, Innovation & Technology at Illinois Department of Commerce and Economic Opportunity (DCEO), is dedicated to supporting startups in the state.